FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden

0.5

hours per response:

Check this box if no longer subject to	ST
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(h)	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or se	ection 30(h) of the Ir	ivestme	nt Con	npany Act of 19	40					
1. Name and Address of Reporting Person [*] Sablich Kim					2. Issuer Name and Ticker or Trading Symbol <u>Myovant Sciences Ltd.</u> [MYOV]							tionship of Reporting all applicable) Director	Person(s) to Issuer 10% Owner		
											X	Officer (give title below)		Other (sp below)	pecify
(Last) (First) (Middle) C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY					3. Date of Earliest Transaction (Month/Day/Year) 08/26/2019							Chief Comr	nercial O	Officer	
(Street) BRISBA	NE	CA	94005	4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv X	vidual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)		(State)	(Zip)												
			Table I - No	n-Deriva	ative S	Securities Acq	uired,	Disp	posed of, o	r Bene	ficially O	wned			
Date			2. Transact Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities A Disposed Of (I			5. Amount of Securities Beneficially Owned Following Reported			7. Nature of Indirect Beneficial Ownership	
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
Common Shares 08/20					2019		A		37,415 ⁽¹⁾	A	\$0.00	67,115	D		
			Table II -			ecurities Acqu alls, warrants,						ned			
1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deemed Execution Date,	4. Transact		. Number of Perivative Securities		6. Date Exercisable and Expiration Date 7. Title and of Securitie			mount 8. Price of 9. Num Derivative derivati		.0. Dwnership	11. Nature of Indirect	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration N		Amount or Number of Shares	Reported Transaction(s) (Instr. 4)			
Stock Option (Right to Buy)	\$17.28	08/26/2019		D			133,500 ⁽²⁾	(3)	12/16/2028	Common Shares	133,500	\$0.00	0	D	
Stock Option (Right to Buy)	\$7.78	08/26/2019		A		133,500 ⁽²⁾		(3)	12/16/2028	Common Shares	133,500	\$0.00	133,500	D	
Stock Option (Right to Buy)	\$24.44	08/26/2019		D			66,130 ⁽²⁾	(4)	04/04/2029	Common Shares	66,130	\$0.00	0	D	
Stock Option (Right to Buy)	\$7.78	08/26/2019		A		66,130 ⁽²⁾		(4)	04/04/2029	Common Shares	66,130	\$0.00	66,130	D	

Explanation of Responses:

1. The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date; and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.

2. Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option.

3. 1/4 of the common shares underlying this option vest on December 17, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.

4. 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.

Remarks:

/s/ Matthew Lang, Attorney-in-

fact

08/27/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.